FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387143003> ?p ?o ?g. }

• W4387143003 abstract "Booster COVID-19 vaccines have shown efficacy in clinical trials and effectiveness in real-world data against symptomatic and severe illness. However, some people still become infected with SARS-CoV-2 following a third (booster) vaccination. This study describes the characteristics of SARS-CoV-2 illness following a third vaccination and assesses the risk of progression to symptomatic disease in SARS-CoV-2 infected individuals with time since vaccination.This prospective, community-based, case-control study used data from UK-based, adult (≥18 years) users of the COVID Symptom Study mobile application, self-reporting a first positive COVID-19 test between June 1, 2021 and April 1, 2022. To describe the characteristics of SARS-CoV-2 illness following a third vaccination, we selected cases and controls who had received a third and second dose of monovalent vaccination against COVID-19, respectively, and reported a first positive SARS-CoV-2 test at least 7 days after most recent vaccination. Cases and controls were matched (1:1) based on age, sex, BMI, time between first vaccination and infection, and week of testing. We used logistic regression models (adjusted for age, sex, BMI, level of social deprivation and frailty) to analyse associations of disease severity, overall disease duration, and individual symptoms with booster vaccination status. To assess for potential waning of vaccine effectiveness, we compared disease severity, duration, and symptom profiles of individuals testing positive within 3 months of most recent vaccination (reference group) to profiles of individuals infected between 3 and 4, 4-5, and 5-6 months, for both third and second dose. All analyses were stratified by time period, based on the predominant SARS-CoV-2 variant at time of infection (Delta: June 1, 2021-27 Nov, 2021; Omicron: 20 Dec, 2021-Apr 1, 2022).During the study period, 50,162 (Delta period) and 162,041 (Omicron) participants reported a positive SARS-CoV-2 test. During the Delta period, infection following three vaccination doses was associated with lower odds of long COVID (symptoms≥ 4 weeks) (OR=0.83, CI[0.50-1.36], p < 0.0001), hospitalisation (OR=0.55, CI[0.39-0.75], p < 0.0001) and severe symptoms (OR=0.36, CI[0.27-0.49], p < 0.0001), and higher odds of asymptomatic infection (OR=3.45, CI[2.86-4.16], p < 0.0001), compared to infection following only two vaccination doses. During the Omicron period, infection following three vaccination doses was associated with lower odds of severe symptoms (OR=0.48, CI[0.42-0.55], p < 0.0001). During the Delta period, infected individuals were less likely to report almost all individual symptoms after a third vaccination. During the Omicron period, individuals were less likely to report most symptoms after a third vaccination, except for upper respiratory symptoms e.g. sneezing (OR=1.40, CI[1.18-1.35], p < 0.0001), runny nose (OR=1.26, CI[1.18-1.35], p < 0.0001), sore throat (OR=1.17, CI[1.10-1.25], p < 0.0001), and hoarse voice (OR=1.13, CI[1.06-1.21], p < 0.0001), which were more likely to be reported. There was evidence of reduced vaccine effectiveness during both Delta and Omicron periods in those infected more than 3 months after their most recent vaccination, with increased reporting of severe symptoms, long duration illness, and most individual symptoms.This study suggests that a third dose of monovalent vaccine may reduce symptoms, severity and duration of SARS-CoV-2 infection following vaccination. For Omicron variants, the third vaccination appears to reduce overall symptom burden but may increase upper respiratory symptoms, potentially due to immunological priming. There is evidence of waning vaccine effectiveness against progression to symptomatic and severe disease and long COVID after three months. Our findings support ongoing booster vaccination promotion amongst individuals at high risk from COVID-19, to reduce severe symptoms and duration of illness, and health system burden. Disseminating knowledge on expected symptoms following booster vaccination may encourage vaccine uptake." @default.
• W4387143003 created "2023-09-29" @default.
• W4387143003 creator A5001335642 @default.
• W4387143003 creator A5002163035 @default.
• W4387143003 creator A5007411844 @default.
• W4387143003 creator A5009232210 @default.
• W4387143003 creator A5013079189 @default.
• W4387143003 creator A5015471815 @default.
• W4387143003 creator A5018652821 @default.
• W4387143003 creator A5021699912 @default.
• W4387143003 creator A5023117088 @default.
• W4387143003 creator A5029347425 @default.
• W4387143003 creator A5043454608 @default.
• W4387143003 creator A5044422433 @default.
• W4387143003 creator A5045287606 @default.
• W4387143003 creator A5045425207 @default.
• W4387143003 creator A5069877317 @default.
• W4387143003 creator A5072656965 @default.
• W4387143003 creator A5082106258 @default.
• W4387143003 creator A5084690770 @default.
• W4387143003 date "2023-09-01" @default.
• W4387143003 modified "2023-10-16" @default.
• W4387143003 title "SARS-CoV-2 infection following booster vaccination: illness and symptom profile in a prospective, observational community-based case-control study" @default.
• W4387143003 cites W1967314461 @default.
• W4387143003 cites W2093535757 @default.
• W4387143003 cites W2502641688 @default.
• W4387143003 cites W3023519397 @default.
• W4387143003 cites W3087935000 @default.
• W4387143003 cites W3136444236 @default.
• W4387143003 cites W3157666998 @default.
• W4387143003 cites W3217698631 @default.
• W4387143003 cites W4205240144 @default.
• W4387143003 cites W4207003944 @default.
• W4387143003 cites W4224279482 @default.
• W4387143003 cites W4225386205 @default.
• W4387143003 cites W4225745323 @default.
• W4387143003 cites W4226229183 @default.
• W4387143003 cites W4226246286 @default.
• W4387143003 cites W4226391429 @default.
• W4387143003 cites W4229081322 @default.
• W4387143003 cites W4281648214 @default.
• W4387143003 cites W4297242770 @default.
• W4387143003 cites W4306729513 @default.
• W4387143003 cites W4312122365 @default.
• W4387143003 cites W4313331922 @default.
• W4387143003 cites W4315620770 @default.
• W4387143003 cites W4317831218 @default.
• W4387143003 cites W4319057949 @default.
• W4387143003 cites W4321523276 @default.
• W4387143003 cites W4324307863 @default.
• W4387143003 doi "https://doi.org/10.1016/j.jinf.2023.08.009" @default.
• W4387143003 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37777159" @default.
• W4387143003 hasPublicationYear "2023" @default.
• W4387143003 type Work @default.
• W4387143003 citedByCount "0" @default.
• W4387143003 crossrefType "journal-article" @default.
• W4387143003 hasAuthorship W4387143003A5001335642 @default.
• W4387143003 hasAuthorship W4387143003A5002163035 @default.
• W4387143003 hasAuthorship W4387143003A5007411844 @default.
• W4387143003 hasAuthorship W4387143003A5009232210 @default.
• W4387143003 hasAuthorship W4387143003A5013079189 @default.
• W4387143003 hasAuthorship W4387143003A5015471815 @default.
• W4387143003 hasAuthorship W4387143003A5018652821 @default.
• W4387143003 hasAuthorship W4387143003A5021699912 @default.
• W4387143003 hasAuthorship W4387143003A5023117088 @default.
• W4387143003 hasAuthorship W4387143003A5029347425 @default.
• W4387143003 hasAuthorship W4387143003A5043454608 @default.
• W4387143003 hasAuthorship W4387143003A5044422433 @default.
• W4387143003 hasAuthorship W4387143003A5045287606 @default.
• W4387143003 hasAuthorship W4387143003A5045425207 @default.
• W4387143003 hasAuthorship W4387143003A5069877317 @default.
• W4387143003 hasAuthorship W4387143003A5072656965 @default.
• W4387143003 hasAuthorship W4387143003A5082106258 @default.
• W4387143003 hasAuthorship W4387143003A5084690770 @default.
• W4387143003 hasConcept C121332964 @default.
• W4387143003 hasConcept C12590561 @default.
• W4387143003 hasConcept C126322002 @default.
• W4387143003 hasConcept C1276947 @default.
• W4387143003 hasConcept C147483822 @default.
• W4387143003 hasConcept C151956035 @default.
• W4387143003 hasConcept C188816634 @default.
• W4387143003 hasConcept C203014093 @default.
• W4387143003 hasConcept C203165030 @default.
• W4387143003 hasConcept C22070199 @default.
• W4387143003 hasConcept C23131810 @default.
• W4387143003 hasConcept C2779134260 @default.
• W4387143003 hasConcept C2780801004 @default.
• W4387143003 hasConcept C71924100 @default.
• W4387143003 hasConceptScore W4387143003C121332964 @default.
• W4387143003 hasConceptScore W4387143003C12590561 @default.
• W4387143003 hasConceptScore W4387143003C126322002 @default.
• W4387143003 hasConceptScore W4387143003C1276947 @default.
• W4387143003 hasConceptScore W4387143003C147483822 @default.
• W4387143003 hasConceptScore W4387143003C151956035 @default.
• W4387143003 hasConceptScore W4387143003C188816634 @default.
• W4387143003 hasConceptScore W4387143003C203014093 @default.
• W4387143003 hasConceptScore W4387143003C203165030 @default.
• W4387143003 hasConceptScore W4387143003C22070199 @default.
• W4387143003 hasConceptScore W4387143003C23131810 @default.
• W4387143003 hasConceptScore W4387143003C2779134260 @default.

• next